Can automated sample preparation systems handle low-volume clinical samples?

Yes, automated sample preparation systems can handle low-volume clinical samples, but the degree of success depends on the system’s design, the sample matrix, and the volume range it was built to accommodate. Modern automated platforms have advanced significantly, with many now supporting sample inputs from as little as 10 mL, making them genuinely viable for small-volume workflows. The sections below unpack the practical challenges, the system types best suited to the task, and what laboratories need to verify before making the switch.

What makes low-volume clinical samples difficult to process automatically?

Low-volume clinical samples are difficult to process automatically because small volumes amplify every source of error: dead volume in tubing, adsorption onto wetted surfaces, and imprecise fluid handling all become proportionally more damaging when the total sample is measured in microliters rather than milliliters. The smaller the volume, the less margin a system has to recover from any mechanical or chemical inefficiency.

Several factors compound this challenge. Clinical matrices such as plasma, serum, urine, and whole blood contain complex mixtures of proteins, lipids, and salts that can foul instrument components, block cartridges, or interfere with downstream detection. Automated systems designed for high-volume environmental matrices may not be optimized for these viscous, protein-rich fluids.

Adsorption loss is another critical concern. Analytes present at trace concentrations in a small sample volume can bind irreversibly to tubing, valve seats, or sorbent materials before they ever reach the collection vessel. In manual workflows, an experienced analyst can compensate with additional rinse steps or adjusted technique. Automated platforms must have this built into their method parameters from the outset.

Finally, evaporation during processing becomes a measurable variable at small volumes. Even brief exposure to ambient conditions or elevated temperatures during automated steps can alter the final concentration, introducing systematic bias into results.

Which types of automated systems are designed for small sample volumes?

Automated Solid Phase Extraction (SPE) systems are the most widely used platform for processing small sample volumes in structured, reproducible workflows. These systems use cartridges or disk formats to retain target analytes while washing away matrix interferences, then elute with a defined solvent volume, a process that scales well to low-volume inputs when the right cartridge format is selected.

Cartridge compatibility is a key differentiator between systems. Platforms that support 1 mL and 3 mL cartridges alongside larger formats offer genuine flexibility for low-volume clinical work. For instance, the SPE2000 automated platform supports cartridges from 1 mL to 12 mL and handles sample volumes starting from 10 mL, giving laboratories a practical entry point for smaller-volume applications alongside higher-volume environmental workflows.

Vacuum centrifuge concentrators are another relevant tool. After extraction, small-volume eluates often need to be reduced to a precise end volume for injection. Systems that combine controlled heat and vacuum in a centrifugal format can process over 60 individual 2 mL vials in a single run, making the concentration step after automated extraction both fast and reproducible.

Parallel evaporation systems with nitrogen blow-down capability also serve this role, particularly when analytes are heat-sensitive or when solvent compatibility is a concern. The ability to control needle depth, temperature, and gas flow independently across multiple channels is especially valuable when working with small, irreplaceable clinical samples where any over-evaporation represents an unrecoverable loss.

How does cross-contamination risk change with smaller sample volumes?

Cross-contamination risk increases with smaller sample volumes because the ratio of carry-over volume to total sample volume grows. A residual 5 µL of a previous sample in a shared flow path is negligible when processing 500 mL of water but represents a meaningful fraction of a 1 mL clinical aliquot. This makes the design of the flow path, and whether samples contact the system directly, a critical selection criterion.

The most effective engineering solution is to eliminate direct contact between the sample and the instrument’s internal surfaces entirely. In systems where samples pass through dedicated disposable cartridges and the instrument’s wetted path is limited to solvent delivery, the risk of sample-to-sample carry-over is structurally minimized rather than managed through washing protocols alone.

For clinical applications involving high-potency analytes such as hormones, immunosuppressants, or endocrine disruptors, even sub-percent carry-over can compromise result integrity. Laboratories should evaluate any automated platform by reviewing its carry-over specifications under worst-case conditions, not just typical performance claims, and confirm that the system architecture matches the contamination risk profile of their specific analyte panel.

Inert flow path materials also matter. Systems constructed with components free of materials that adsorb or leach into the sample stream reduce both contamination and background interference, which is particularly important when target analytes are present at parts-per-trillion concentrations in a limited clinical volume.

Can automated sample prep systems replace manual handling for clinical matrices?

Automated sample preparation systems can replace manual handling for many clinical matrix workflows, but not universally. The replacement is most successful when the target analytes, matrix type, and required throughput are well matched to the system’s validated capabilities. For routine, high-volume panels where reproducibility matters more than flexibility, automation typically outperforms manual handling on every measurable metric.

Where manual handling retains an advantage is in non-routine or highly variable sample types. Clinical research samples, rare biospecimens, or matrices with unpredictable physical properties may require real-time judgment calls that current automated platforms cannot replicate. An experienced analyst can respond to a hemolyzed sample or an unexpected precipitate in a way that a programmed system cannot without a defined exception protocol.

That said, the practical case for automation in clinical sample preparation is strong for several reasons:

Reproducibility: Automated systems apply identical conditions to every sample, eliminating the analyst-to-analyst and day-to-day variability that affects manual workflows.
Throughput: Platforms capable of processing multiple samples in parallel dramatically reduce the time per sample compared to sequential manual processing.
Analyst safety: Reduced direct solvent handling lowers occupational exposure, particularly relevant in clinical environments where solvent use is closely regulated.
Audit trails: Automated systems generate instrument logs that support regulatory compliance and method traceability requirements in accredited laboratories.

The decision to automate should be driven by a realistic assessment of sample volume, matrix consistency, required sensitivity, and the laboratory’s capacity to validate the automated method to the same standard as the manual procedure it replaces.

What validation steps are required before automating clinical sample preparation?

Before automating clinical sample preparation, laboratories must complete a structured method validation that demonstrates the automated process meets the same performance criteria as the reference method. This typically includes assessing accuracy, precision, linearity, specificity, carry-over, and recovery across the full range of expected sample concentrations and matrix types.

The validation sequence generally follows this order:

System suitability testing: Confirm the instrument operates within specification before any method-specific work begins. This includes flow rate accuracy, pressure stability, and cartridge seating.
Recovery assessment: Spike known concentrations of target analytes into representative matrix blanks and measure recovery across low, mid, and high concentration levels. Recovery should be consistent and within method-defined acceptance criteria.
Precision testing: Run replicate samples within a single run (repeatability) and across multiple runs on different days (intermediate precision) to establish the method’s variability profile.
Carry-over evaluation: Process a high-concentration sample followed by a blank to quantify residual signal. Carry-over must fall below a defined threshold relative to the lowest calibration standard.
Matrix effects assessment: Compare analyte response in neat solvent versus extracted matrix to identify ion suppression or enhancement that could affect quantitative accuracy.
Stability testing: Confirm that samples processed under automated conditions, including any hold times in the instrument queue, do not degrade in a way that affects result accuracy.

For laboratories operating under ISO 17025 accreditation or regulatory frameworks such as those governing clinical diagnostics, all validation data must be documented, reviewed, and retained as part of the quality management system. Method transfer documentation is also required when an automated method replaces an existing accredited manual procedure, demonstrating equivalence before the new method enters routine use.

How DSP-Systems supports automated sample preparation for specialized analytical workflows

DSP-Systems specializes in automated sample preparation and cleanup systems designed for laboratories analyzing persistent organic pollutants, PFAS, pesticides, and other environmental contaminants. While the company’s core focus is environmental and food safety matrices, the platforms it supplies address many of the same technical challenges relevant to low-volume and complex-matrix sample preparation. Key capabilities include:

Flexible SPE automation: The SPE2000 supports 1 mL to 12 mL cartridges and sample volumes from 10 mL upward, with quick rack switching for different volume formats.
Cross-contamination elimination: GO-EHT automated cleanup systems prevent direct sample-to-system contact, structurally removing carry-over risk.
Inert flow path design: LabTech SPE systems feature fully inert, Teflon-free flow paths suited to PFAS, endocrine disruptors, and other sensitive analyte classes.
Concentration solutions: CentriVap and MultiVap evaporation platforms handle post-extraction concentration with precision, supporting both small vial formats and larger volumes.
Method development support: DSP-Systems works with ISO 17025 accredited laboratories on method development and validation, including configuration in line with EPA and CEN standards.

If your laboratory is evaluating automated sample preparation platforms or needs support validating a new automated workflow, contact DSP-Systems to discuss which system configuration best fits your sample types, throughput requirements, and regulatory framework.

Veelgestelde vragen

How do I know if my current sample volume is too low for a specific automated SPE system?

Start by requesting the system’s minimum validated sample volume from the manufacturer and comparing it against your typical clinical aliquot size. Pay close attention to the dead volume specifications for the tubing and cartridge format, since a system with a 5 mL dead volume is functionally incompatible with a 1 mL sample input regardless of its advertised minimum. If possible, ask for performance data — recovery and precision results — generated at your specific volume range, not just at the system’s general lower limit.

What can I do if my automated system is showing poor recovery with clinical samples but performs well with environmental matrices?

Poor recovery in clinical matrices is most commonly caused by adsorption loss, protein fouling of the cartridge, or an incompatible wash/elution solvent profile — issues that are far less pronounced in cleaner environmental matrices. Start by reviewing the cartridge sorbent chemistry and confirming it is appropriate for your target analytes in a protein-rich matrix; protein precipitation prior to loading is often a practical fix that dramatically improves downstream recovery. You should also audit the system’s wetted surfaces for materials known to adsorb your analytes, and consider adding a matrix-matched conditioning step to the method.

Is it possible to automate sample preparation for very small volumes, such as dried blood spots or microsamples?

Yes, but it requires purpose-built or highly configurable platforms rather than standard SPE automation. Dried blood spot (DBS) and volumetric microsampling workflows typically involve an initial reconstitution or extraction step before the cleaned extract enters an automated SPE or dilute-and-shoot workflow, and not all automated systems are designed to handle that upstream step. Laboratories working with these sample types should evaluate systems specifically validated for microsampling formats and confirm that the full workflow — from card extraction through final concentration — can be integrated or at minimum seamlessly connected.

How many samples can a typical automated SPE system process in a single unattended run, and does batch size affect result quality?

Batch size capacity varies widely by platform, ranging from 12-position systems suited to low-throughput clinical research up to 96-well or multi-rack configurations for high-volume routine testing. Result quality can be affected by batch size if samples queue for extended periods at ambient temperature, which is why stability testing under hold conditions is a required part of method validation. To protect result integrity, configure the system’s run order and queue time to stay within the stability window established during validation, particularly for labile analytes such as certain hormones or metabolites.

What are the most common mistakes laboratories make when first transitioning from manual to automated clinical sample preparation?

The most frequent mistake is directly transferring manual method parameters — solvent volumes, flow rates, and conditioning steps — into the automated platform without re-optimizing them for the system’s specific fluidics and cartridge geometry. Automated systems deliver solvents with far greater consistency than manual pipetting, which often means that method parameters need to be tightened rather than simply copied. A second common error is underestimating the validation workload: replacing a manual method with an automated one requires a formal equivalence demonstration, not just a side-by-side comparison of a handful of samples.

Do automated sample preparation systems require specialist staff to operate and maintain, or can existing laboratory personnel manage them?

Most modern automated SPE platforms are designed for operation by standard laboratory staff with basic instrument training, and routine daily operation — loading samples, initiating runs, and performing basic maintenance — typically does not require a specialist. However, method development, troubleshooting non-routine failures, and performing periodic preventive maintenance do benefit from staff who have completed manufacturer-led training or have prior experience with automated liquid handling systems. Building internal competency through initial vendor training and maintaining access to manufacturer technical support will cover the majority of operational needs for most clinical laboratories.

How should I approach regulatory or accreditation bodies when introducing an automated sample prep method to replace an accredited manual procedure?

The key requirement for most accreditation frameworks, including ISO 17025, is demonstrating method equivalence through a structured validation that generates documented evidence the automated method performs within the same acceptance criteria as the manual procedure it replaces. Prepare a method transfer or equivalence report that includes side-by-side performance data for accuracy, precision, recovery, and carry-over, and present this alongside your updated method documentation before the new procedure enters routine use. Engaging your accreditation body early in the process — rather than notifying them after implementation — is strongly recommended, as requirements for scope extension or method change notification vary between bodies and regions.

Gerelateerde artikelen

Deze inhoud is gegenereerd met behulp van AI en kan fouten bevatten.